Small-Molecule Antibiotics & Resistance Inhibitors
Commercial sector
Small-Molecule Antibiotics & Resistance Inhibitors
Companies developing novel small-molecule antibacterial agents, including new antibiotic classes, beta-lactamase inhibitors (including metallo-beta-lactamase inhibitors), efflux pump inhibitors, and antibiotic potentiators/adjuvants intended for systemic treatment of drug-resistant bacterial infections.
Companies83
Commercial products251
Technology classes5
Countries17
Patents746
Profiled companies
Products
- ShionogiJapan3
- Venatorx PharmaceuticalsUnited States4
- AntabioFrance10
- ArietisUnited States2
- Basilea PharmaceuticaSwitzerland4
- BUGWORKS ResearchIndia2
+ 77 more